Heather Van Epps
About Heather Van Epps
Heather Van Epps serves as the Executive Director and Head of Therapeutic Research at Generate Biomedicines, emphasizing cross-functional teamwork to enhance therapeutic research outcomes. With extensive experience in both early discovery and clinical stages, she has contributed significantly to the field through various roles in notable organizations.
Current Role at Generate Biomedicines
Heather Van Epps serves as the Executive Director and Head of Therapeutic Research at Generate Biomedicines, a position she has held since 2023. In this role, she emphasizes the importance of building effective cross-functional teams to achieve meaningful and timely results in therapeutic research. Her leadership is focused on advancing therapeutic programs that address patient needs through a multidisciplinary approach.
Previous Experience at Seagen
Prior to her current role, Heather Van Epps held multiple positions at Seagen. She worked as Research Director for Early-Stage Clinical Programs for six months in 2022. Before that, she served as Associate Director of Antibody Discovery from 2018 to 2021 and as Principal Scientist from 2015 to 2018. Her tenure at Seagen contributed to her extensive experience in therapeutic research.
Academic Background
Heather Van Epps completed her Ph.D. in Biochemistry at the University of Washington, where she studied from 1997 to 2004. She also holds a Bachelor of Science in Biochemistry from the University of Illinois Urbana-Champaign, where she studied from 1995 to 1997. Her academic background provides a strong foundation for her work in therapeutic research.
Past Academic Role
Before transitioning to the biotechnology industry, Heather Van Epps served as an Assistant Professor of Biology at Western Washington University from 2008 to 2011. This role allowed her to engage in academic research and education, further enhancing her expertise in the biological sciences.
Focus on Therapeutic Research
Heather Van Epps has a strong focus on building therapeutics through a multidisciplinary approach driven by the biology of disease and patient needs. Her experience spans from early discovery to clinical stage therapeutic research, highlighting her commitment to making meaningful changes for patients.